SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-09-019896
Filing Date
2009-02-05
Accepted
2009-02-05 14:43:51
Documents
3
Period of Report
2009-01-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d8k.htm 8-K 20441
2 AMENDMENT TO THE RIGHTS AGREEMENT DATED AS OF FEBRUARY 5, 2009 dex41.htm EX-4.1 13251
3 PDL BIOPHARMA, INC. CODE OF BUSINESS CONDUCT dex141.htm EX-14.1 56342
  Complete submission text file 0001193125-09-019896.txt   92169
Mailing Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451
Business Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451 775-832-8500
PDL BIOPHARMA, INC. (Filer) CIK: 0000882104 (see all company filings)

IRS No.: 943023969 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19756 | Film No.: 09572674
SIC: 2836 Biological Products, (No Diagnostic Substances)